Overtape Transdermal Delivery System Patent - AdhexPharma
Summary
The European Patent Office (EPO) published patent application EP3412283A1 for AdhexPharma SAS covering an overtape for a transdermal delivery system. The patent is designated for all European member states and several additional countries. IPC classifications indicate the technology relates to analgesics (A61P 25/04) and transdermal pharmaceutical delivery (A61K 9/70).
What changed
The EPO granted AdhexPharma SAS exclusive rights to an overtape technology for transdermal drug delivery systems. The patent provides intellectual property protection across all designated European contracting states and additional countries. IPC classification A61P 25/04 indicates application in analgesics, while A61K 9/70 covers the transdermal delivery format.
Pharmaceutical manufacturers developing competing transdermal delivery systems should assess freedom to operate before commercialization. The patent affects companies in the transdermal drug delivery space, requiring clearance analyses and potentially licensing negotiations with AdhexPharma.
What to do next
- Monitor patent for potential infringement concerns
- Conduct freedom-to-operate analysis for competing transdermal delivery systems
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
OVERTAPE FOR A TRANSDERMAL DELIVERY SYSTEM
Publication EP3412283A1 Kind: A1 Apr 08, 2026
Applicants
AdhexPharma SAS
Inventors
Rodler, Stefanie
IPC Classifications
A61K 9/70 20060101AFI20181107BHEP A61K 31/485 20060101ALI20181107BHEP A61P 25/04 20060101ALI20181107BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.